Should we continue methylphenidate treatment despite orofacial or extremity dyskinesias?

Kazancı S. Y., TARAKÇIOĞLU M. C., Bulbul L., Saglam N. O., Hatipoglu S.

Klinik Psikofarmakoloji Bulteni, cilt.25, sa.4, ss.399-402, 2015 (SCI-Expanded, Scopus, TRDizin) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 4
  • Basım Tarihi: 2015
  • Doi Numarası: 10.5455/bcp.20150902042021
  • Dergi Adı: Klinik Psikofarmakoloji Bulteni
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.399-402
  • Anahtar Kelimeler: Attention-deficit/hyperactivity disorder, Methylphenidate, Orofacial dyskinesia
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Attention-deficit/hyperactivity disorder (ADHD) is the most common neuropsychiatric disease affecting 5.3% of school-aged children. Methylphenidate is the primary stimulant, which has been used widely more than 60 years to treat ADHD. In this paper 3 cases with orofacial and/or limb dyskinesia after methylphenidate administration are reported. In 2 of our patients, continuation of the methylphenidate treatment did not cause recurrent dyskinesia. We thought that despite dyskinetic side effects, in cases with normal IQ level, continuation of methylphenidate treatment may be safe and do not cause any recurrent dyskinetic movements. Despite dyskinesia, one more chance may be given to methylphenidate treatment.